But that has not stopped patients and health care providers from turning to gabapentin (whose brand names include Neurontin) for a startling array of other conditions, including sciatica, neuropathy ...
The Global non-opioid pain relief device market, which was valued at US$ 5,444.8 million in 2023, is expected to reach US$ 11,440.6 million by 2032, signaling a significant growth trajectory at a CAGR ...
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient ...